PHAXIAM Therapeutics S.A.
NASDAQ: PHXM0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Eric Soyer
- Employees
- 49
- Headquarters
- Lyon, France
- IPO year
- 2017
- Market cap
- $19.9M
- Website
- https://www.erytech.com
Loading PHXM…
Loading profile data…Frequently asked questions about PHXM
What does PHAXIAM Therapeutics S.A. (PHXM) do?
PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating therapies for drug-resistant bacterial infections, operating in both France and the U.S. The company's pipeline includes eryaspase, which is currently undergoing Phase 3 clinical trials for advanced pancreatic cancer (second-line treatment) and Phase 2 studies for triple...
Where does PHXM trade?
PHAXIAM Therapeutics S.A. (PHXM) trades on the NASDAQ Capital Market.
What sector is PHXM in?
PHAXIAM Therapeutics S.A. (PHXM) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of PHAXIAM Therapeutics S.A.?
Eric Soyer is the chief executive officer of PHAXIAM Therapeutics S.A. (PHXM).
Where is PHAXIAM Therapeutics S.A. headquartered?
PHAXIAM Therapeutics S.A. is headquartered in France.
Does PHXM pay a dividend?
PHAXIAM Therapeutics S.A. (PHXM) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did PHXM go public?
PHAXIAM Therapeutics S.A. (PHXM) completed its initial public offering in 2017.
Is PHXM an ADR?
Yes — PHXM is an American Depositary Receipt; its underlying shares trade on a non-US exchange. PHAXIAM Therapeutics S.A. reporting and dividends follow the underlying issuer.